芦可替尼治疗糖皮质激素难治性或依赖性慢性移植物抗宿主病:III期REACH3研究3年最终分析
REACH3研究比较芦可替尼与最佳可用疗法(BAT)治疗糖皮质激素难治性/依赖性慢性移植物抗宿主病(SR/D-cGVHD)的3年随访结果。在329例随机分组患者中,芦可替尼组中位无失败生存期(FFS)为38.4个月,BAT组为5.7个月(HR 0.36,95%CI 0.27-0.49)。芦可替尼提供更长的FFS和缓解持续时间(DOR),3年随访中疗效持续且安全性可控。
要点
- 芦可替尼组中位FFS为38.4个月,BAT组为5.7个月,HR 0.36(95%CI 0.27-0.49)。
- 芦可替尼组中位DOR未达到,BAT组为6.4个月;36个月维持缓解概率分别为59.6%和26.7%。
- 70例从BAT交叉至芦可替尼的患者第24周ORR为50.0%,交叉期间最佳总缓解为81.4%。
核心结论
- 芦可替尼较BAT提供更长的FFS和DOR,3年随访中显示持续疗效和可控安全性。
研究设计与样本
- III期REACH3研究(NCT03112603)将329例SR/D-cGVHD患者随机分配至芦可替尼组(165例)或BAT组(164例)。
- 患者接受芦可替尼10 mg每日两次或BAT治疗24周,此后(第24-156周)继续随机治疗、进入长期生存随访或从BAT交叉至芦可替尼。
主要发现
- 中位FFS:芦可替尼组38.4个月 vs BAT组5.7个月(HR 0.36,95%CI 0.27-0.49)。
- 中位DOR:芦可替尼组未达到 vs BAT组6.4个月。
- 36个月FFS概率:芦可替尼组56.5% vs BAT组18.2%;36个月维持缓解概率:芦可替尼组59.6% vs BAT组26.7%。
- 中位总生存未达到;非复发死亡和恶性肿瘤复发/再发事件均较少。
- 70例交叉至芦可替尼的患者第24周ORR为50.0%,交叉期间最佳总缓解为81.4%,与随机分组患者主要分析一致;未观察到新的安全性信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In REACH3 (ClinicalTrials.gov identifier: NCT03112603), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD). Patients received ruxolitinib (10 mg twice daily) or BAT for 24 weeks; thereafter (weeks 24-156), patients continued randomized treatment, entered long-term survival follow-up, or crossed over from BAT to ruxolitinib. In 329 randomly assigned patients (ruxolitinib: 165; BAT: 164), the median failure-free survival (FFS) was 38.4 months for ruxolitinib versus 5.7 months for BAT (hazard ratio, 0.36 [95% CI, 0.27 to 0.49]). Median duration of response (DOR) was not reached for ruxolitinib versus 6.4 months for BAT. Ruxolitinib-treated patients had a higher probability of FFS (ruxolitinib: 56.5%; BAT: 18.2%) and maintaining a response (ruxolitinib: 59.6%; BAT: 26.7%) at 36 months. Median overall survival was not reached. Nonrelapse mortality and malignancy relapse/recurrence events were low. In 70 patients who crossed over to ruxolitinib, the overall response rate (50.0%) at week 24 and best overall response (81.4%) during the crossover period were consistent with the primary analysis of randomly assigned patients. No new safety signals were observed. Ruxolitinib provided longer FFS and DOR than BAT, demonstrating sustained efficacy and manageable safety over 3 years of follow-up in patients with SR/D-cGVHD.
引用
- Zeiser R, Russo D, Ram R, et al. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. J Clin Oncol. 2025. PMID: 40561385. doi:10.1200/JCO-24-02477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。